Credit Suisse Maintains a Hold Rating on Intellia Therapeutics (NTLA)
In a report released yesterday, Martin Auster from Credit Suisse maintained a Hold rating on Intellia Therapeutics (NTLA), with a price target of $21.00. The company’s shares closed last Friday at $19.92.
According to TipRanks.com, Auster is a 5-star analyst with an average return of 16.1% and a 60.8% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Intellia Therapeutics is a Moderate Buy with an average price target of $32.83, implying a 67.9% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.56 and a one-year low of $9.18. Currently, Intellia Therapeutics has an average volume of 975.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.